Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential vs Concurrent Epirubicin and Docetaxel in High Risk Node-Negative Breast Cancer
NCT00424606Phase 3Completed
- Sponsor
- Hellenic Oncology Research Group
- Start
- Jun 2001
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of docetaxel in breast cancer, sponsored by Hellenic Oncology Research Group. Started Jun 2001; status: completed.
02
Drugs
docetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00424606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00424606.